Want to join the conversation?
Stifel Nicolaus analyst Robert McCarthy probes $ROP on the product launches in Medical business and the drivers of 6% organic growth for 2H16. CFO John Humphrey says that the pipeline is growing more rapidly. CEO Brian Jellison says that the market conditions around new customer adds give the company an opportunity to better in 2H16.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.